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Protein phosphorylation, while critical to cellular
behavior, has been undercharacterized in pluripotent
cells. Therefore, we performed phosphoproteomic
analyses of human embryonic stem cells (hESCs)
and their differentiated derivatives. A total of 2546
phosphorylation sites were identified on 1602 phos-
phoproteins; 389 proteins contained more phos-
phorylation site identifications in undifferentiated
hESCs, whereas 540 containedmore such identifica-
tions in differentiated derivatives. Phosphoproteins
in receptor tyrosine kinase (RTK) signaling pathways
were numerous in undifferentiated hESCs. Cellular
assays corroborated this observation by showing
that multiple RTKs cooperatively supported undiffer-
entiated hESCs. In addition to bFGF, EGFR, VEGFR,
and PDGFR activation was critical to the undifferen-
tiated state of hESCs. PDGF-AA complemented a
subthreshold bFGF concentration to maintain undif-
ferentiated hESCs. Also consistent with phospho-
proteomics, JNK activity participated inmaintenance
of undifferentiated hESCs. These results support the
utility of phosphoproteomic data, provide guidance
for investigating protein function in hESCs, and
complement transcriptomics/epigenetics for broad-
ening our understanding of hESC fate determination.
INTRODUCTION
Human embryonic stem cells (hESCs) are amodel developmental
system that may have potential clinical value for mitigating
diseases. Mechanisms of hESC fate determination are not well
defined, although there has been progress in elucidating molec-
ular circuitry of self-renewing ESCs. Transcriptional profiles of
hESCs (Brandenberger et al., 2004; Sato et al., 2003; Sperger
et al., 2003) and more limited ChIP-on-chip (Boyer et al., 2005)
andproteomic (Bendall et al., 2007;VanHoofet al., 2006) analyses204 Cell Stem Cell 5, 204–213, August 7, 2009 ª2009 Elsevier Inc.suggest mechanisms underlying hESC self-renewal and differen-
tiation. In addition to transcriptional and translational regulation,
cell-fate determination is controlled by protein phosphorylation,
a critical determinant of cell signaling (Mann et al., 2002; Schles-
singer, 2000). Recent phosphoproteomic analyses of human
mesenchymal stemcells identified716and703proteinphosphor-
ylation sites (Thingholm et al., 2008a, 2008b). However, protein
phosphorylation has not been well characterized in pluripotent
cells. Therefore, we performed a large-scale multidimensional
liquid chromatography (MDLC)- tandem mass spectrometry
(MS/MS)-based phosphoproteomic analysis of undifferentiated
hESCs and their differentiated derivatives for identification of
protein phosphorylation sites in these cells.
UndifferentiatedhESCswereculturedunder feeder-free condi-
tions with bFGF. Comparable differentiated derivatives were ob-
tained by removal of bFGF and treatment with retinoic acid (RA),
which induces nearly complete, albeit nonspecific, differentiation
to a heterogeneous population of cells. Removal of bFGF alone
does not result in complete differentiation, whereas concurrent
RA treatment causes virtually complete loss of the undifferenti-
ated population in 4 days (required for this type of analysis). Our
data provide a freely available resource of protein phosphoryla-
tion sites in hESCs and differentiated derivatives (http://www.
ebi.ac.uk/pride/). These data have begun to prove informative
and predictive. For example, as proof of concept, pathway anal-
yses of the phosphoproteins suggested potential responses of
hESCs to perturbations of receptor tyrosine kinase (RTK)
signaling pathways. To test some RTK pathways for a role in
the maintenance of undifferentiated hESCs, we treated hESC
cultureswith selected agonists or antagonists of thesepathways.
Their effectswere consistentwith predictions of the phosphopro-
teomic analyses. Furthermore, the data suggested previously
unidentified protein roles in hESC self-renewal or differentiation,
thus providing extensive guidance for future research.
RESULTS
Phosphoproteomic Analysis of hESCs
Because phosphoproteomic analysis is challenging (Mann et al.,
2002) and has not been reported in hESCs, we chose to analyze
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Human ESC Phosphoproteomicsthe well-characterized hESC line H1 (WiCell; WA01) (Thomson
et al., 1998), which has been used in molecular studies of hESCs
(Bendall et al., 2007; Brandenberger et al., 2004; Wang et al.,
2007). Fifty-nine hESC lines, including H1, showed remarkable
conservation of hESC markers (Adewumi et al., 2007), which
provided confidence that our findings would be representative.
Before analyzing protein phosphorylation, the undifferentiated
hESCmarkersOCT4 (Thomsonet al., 1998) andSSEA-4 (Reubin-
off et al., 2000)were examined to assesswhether thehESCswere
truly undifferentiated under our culture conditions and whether
differentiation was complete. Undifferentiated hESCs were
cultured on Matrigel-coated plates in feeder-free cultures using
conditioned media (CM) that contained 8 ng/ml of added bFGF.
A heterogeneous population of differentiated derivatives of the
hESCs was obtained by removal of bFGF and treatment with
5 mM RA for 4 days. OCT4 was detected in 97% of the hESCs
under the feeder-free conditions,whereas it wasnearly undetect-
able in differentiated derivatives (Figure 1). Similarly, SSEA-4
was positive in the undifferentiated hESCs and nearly absent in
differentiated derivatives. Moreover, the nucleus-to-cytoplasm
ratio, also monitored as an indicator of whether hESCs are undif-
ferentiated or differentiated, was consistent with OCT4 and
SSEA-4 expression (Figure 1). These observations suggested
that our cells represented two distinct populations—‘‘undifferen-
Figure 1. Undifferentiated hESCs Ex-
pressed Markers of Pluripotency, whereas
the Markers Were Downregulated upon
Differentiation
Cells were cultured to yield undifferentiated
hESCs (hESCs), or differentiated hESC derivatives
(derivs) under feeder-free conditions by with-
drawing bFGF and including 5 mMRA in the media
for the final 4 days of culture. Nuclei were stained
with DAPI (A and B; left column).
(A) Cells were stained with antibodies detecting
OCT4 (center column), and OCT4 and DAPI
images were merged (right column).
(B) Cells were stained with antibodies detecting
SSEA-4 (center column), and SSEA-4 and DAPI
images were merged (right column). All photomi-
crographs were at the same magnification. The
scale bar represents 50 mM.
tiated’’ or ‘‘differentiated’’ hESC deriva-
tives—that might then be reliably sub-
jected to phosphoproteomic analysis,
using MDLC-MS/MS technology, that
can result in unbiaseddiscovery of protein
phosphorylation sites (Kruger et al., 2008).
Phosphoproteomic analyses of hESCs
and their differentiated derivatives were
performed using automated MDLC,
a linear ion trap mass spectrometer, and
readily available bioinformatics algo-
rithms. Phosphorylated peptides from
total proteins from undifferentiated
hESCs or their differentiated derivatives
were separated, enriched, and analyzed
using MDLC comprised of strong cation
exchange chromatography (SCX), reversed-phase (RP) desalt-
Fe3+-immobilized metal affinity chromatography (desalt-IMAC),
and RP HPLC coupled to nano-electrospray ionization-tandem
mass spectrometry (ESI-MS/MS; see a schematic diagram in
Figure S1, available online). IMAC, for phosphopeptide enrich-
ment, coupled to RP HPLC-ESI-MS/MS is a robust technique
for phosphoproteomic analyses (Bodenmiller et al., 2007; Brill
et al., 2004; Gruhler et al., 2005), and automation improves
reliability and reproducibility (Ficarro et al., 2005). Because phos-
phorylated proteins are frequently at low abundance, substoi-
chiometrically phosphorylated, and difficult to identify (Mann
et al., 2002), replicate analyses were performed to increase
phosphoproteome coverage. Replicates increase proteome
coverage, especially of lower abundance proteins (Liu et al.,
2004), and the impact of experimental variation in LC-MS/MS
can be minimized by replicates (Washburn et al., 2003). Phos-
phopeptides were identified with high confidence (see Supple-
mental Experimental Procedures). Examples of typical MS/MS
spectra used to identify phosphopeptides are in Figure S2.
To complement identification, extracted ion chromatograms
(XICs) were used to quantify the relative abundance of phospho-
peptides. The normalized abundance of randomly selected
phosphopeptides identified in all four phosphoproteomic anal-
yses (two biological replicates, i.e., phosphopeptides from twoCell Stem Cell 5, 204–213, August 7, 2009 ª2009 Elsevier Inc. 205
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differentiated derivatives) demonstrated relatively low variability
(Table S1). This degree of consistency agrees with previous find-
ings in which proteomic data can be reliably compared among
experiments (Washburn et al., 2003).
In contrast, differential phosphopeptide identification implies
differential phosphopeptide abundance. We used data-depen-
dentMS/MS, andpeptide abundance and identification correlate
in data-dependent MS/MS (Liu et al., 2004). Selected phospho-
peptides identified in undifferentiated hESC or differentiated
derivative cell populations were also quantified using XICs.
Furthermore, signal from each of the selected phosphopeptides
wasmanually sought in theMS/MSdata fromanalyses inwhich it
had not been identified by SEQUEST searches, in order to test
whether the phosphopeptide was detectable and, if so, its rela-
tive abundance among the phosphoproteomic analyses. Only
a fraction of the phosphopeptides not identified in SEQUEST
searches were detectable (via a poor quality MS/MS spectrum)
when searching the raw data (Table S2). However, every phos-
phopeptide that was examined demonstrated a higher normal-
ized abundance in analyses in which it was identified than in
analyses in which it was not identified by SEQUEST searches.
Although lack of identification of a phosphopeptide is not
evidence for its absence, identification versus lack of identifica-
tion implies that the phosphopeptide is likely to be more abun-
dant in the cell population in which it was identified, consistent
with our results (Table S2) and those of others (Liu et al., 2004).
Western blots were performed on proteins from undifferenti-
ated hESCs and differentiated derivatives, using antibodies
recognizing phosphorylation sites previously identified by
MDLC-MS/MS. All nine antibodies that were used recognized
bands with the expected mobility on western blots, providing
confidence in phosphorylation site identifications.
Representative western blots, including normalized integrated
intensities of phosphoprotein bands, are shown in Figure S3.
Phosphorylation of mTOR on Ser2448 was apparently more
abundant inundifferentiated thandifferentiatedcells (FigureS3A),
andmTORSer2448 phosphorylationwas identified in undifferen-
tiated, but not differentiated cells, using MDLC-MS/MS (Table
S3A). PAK1 phosphorylation on Ser144 was identified twice
in undifferentiated cells and once in differentiated cells by
MDLC-MS/MS (Table S5A), and western blots suggested that
PAK1 phosphoserine 144wasmore abundant in undifferentiated
than in differentiated cells (Figure S3B). Antibodies recognizing
PTK2 phosphotyrosine 576/577 suggested that phosphorylation
of this site was more abundant in differentiated derivatives than
undifferentiated hESCs (Figure S3C), consistent with identifica-
tion of PTK2 phosphorylated on Tyr576, using MDLC-MS/MS,
only in differentiated derivatives (Table S4A). Phosphorylation
of CDK1/2/3/5 on Thr14 and Tyr15 (two conserved residues in
all fourCDKproteins)wasmoreabundant in undifferentiated cells
(FigureS3D), andXICpeakareas suggested that phosphorylation
of CDK1/2/3 on Thr14 and Tyr15 was more abundant in undiffer-
entiated cells (Table S1). CDK1, -2, -3, and -5 phosphorylated
on Thr14 and Tyr15 are recognized in western blots (Supple-
mental Experimental Procedures), and the corresponding phos-
phopeptides identified by MDLC-MS/MS (IGEGT*YGVVY and
IGEGTY*GVVY; for brevity, designated as originating from CDK2
in Tables S1 and S5) are identical among CDK1/2/3, whereas the206 Cell Stem Cell 5, 204–213, August 7, 2009 ª2009 Elsevier Inc.corresponding peptide fromCDK5 differs at two amino acid resi-
dues (IGEGT*Y*GTVF), which is easily distinguishable byMS/MS.
The relative abundance of JUN phosphorylated on Ser63, and
HSP27 phosphorylated on Ser82, was similar in undifferentiated
and differentiated cells on western blots (data not shown), and
phosphorylated JUN Ser63 and phosphorylated HSP27 Ser82
were both identified the same number of times in undifferentiated
and differentiated cells (Table S5A), demonstrating further agree-
ment between western blots and MDLC-MS/MS.
If subsequent studies focus on one or a few especially critical
sites of protein phosphorylation, it is advisable to examine the
phosphorylation site using an independent technique. However,
MDLC-MS/MS is reliable for phosphoproteome analysis and can
yield unbiased, large-scale discovery of protein phosphorylation
(Bodenmiller et al., 2007; Brill et al., 2004; Ficarro et al., 2005;
Gruhler et al., 2005; Kruger et al., 2008; Thingholm et al.,
2008a), and our findings support its accuracy. Together, these
results suggest that application of MDLC-MS/MS for identifica-
tion of phosphopeptides was suitable for phosphoproteomic
analysis of undifferentiated hESCs and their differentiated deriv-
atives.
Phosphopeptide identifications are in Tables S3A–S5B. Each
phosphoprotein, from which phosphopeptides were derived,
was classified as either (1) containing more phosphorylation
site identifications in undifferentiated hESCs, (2) containing
more phosphorylation site identifications in differentiated hESC
derivatives, or (3) containing a similar number of phosphorylation
site identifications in both cell populations. A protein is conserva-
tively defined to containmorephosphorylation site identifications
in a cell population if its phosphorylation was identified exclu-
sively in this population or at least 3-fold more frequently than
in the other population; otherwise, the protein is considered to
contain a similar number of phosphorylation site identifications
in populations from both cell states. Although identification of
protein phosphorylation sites was unlikely to be comprehensive,
as implied by studies using different cell types (Bodenmiller et al.,
2007; Mann et al., 2002), among the 2546 nonredundant phos-
phorylation sites, 472 were on proteins containing more phos-
phorylation site identifications in undifferentiated hESCs,
whereas 726 were on proteins containing more phosphorylation
site identifications in differentiated hESC derivatives (Figure 2A).
Of the peptides, 94% were singly phosphorylated, whereas the
rest were doubly phosphorylated, similar to other studies using
IMAC for phosphopeptide enrichment (Bodenmiller et al., 2007;
Thingholm et al., 2008a). Serine, threonine, and tyrosine phos-
phorylation comprised 82%, 14%, and 4% of the sites,
respectively (Tables S3A–S5B), and tyrosine phosphorylation
was relatively prominent in undifferentiated hESCs (Figure 2C).
Among the 1602 proteins, 389 contained more phosphorylation
site identifications in undifferentiated hESCs, whereas 540 con-
tained more phosphorylation site identifications in differentiated
hESC derivatives (Figure 2B).
Transcription factors can reprogram differentiated cell types
to ESC-like cells when ectopically expressed (Takahashi
et al., 2007; Takahashi and Yamanaka, 2006; Yu et al., 2007)
and were the most abundant known phosphoprotein category
(Figures 2G–2I). This observation, not typical of proteomic anal-
yses, could reflect the growing consensus that many transcrip-
tion regulators are important in control of ESC state. Among the
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Human ESC PhosphoproteomicsFigure 2. Number of Protein Phosphoryla-
tion Sites and Phosphoproteins Identified
in hESCs and Their Differentiated Deriva-
tives, Prominence of Tyrosine Phosphory-
lation, Predicted Subcellular Location of
the Phosphoproteins, and Phosphoprotein
Categories
(A and B) (A) Total number of nonredundant phos-
phorylation sites and (B) number of proteins with
more phosphorylation site identifications in undif-
ferentiated hESCs (line H1/WA01) (represented
in red), RA differentiated, H1-hESC derivatives
(represented in gold), or with a similar number of
phosphorylation site identifications in the two cell
populations (represented in gray). The percentage
of the phosphorylation sites and phosphoproteins
in each of the three groups of proteins is shown in
parentheses.
(C) Percentage of nonredundant tyrosine phos-
phorylation sites, among the sites for which the
phosphorylated residue could be defined as
serine, threonine, or tyrosine (94% of all sites),
that were on proteins containing more identified
sites in undifferentiated hESCs, differentiated
hESC derivatives, or that were on proteins with
a similar number of identified sites between undif-
ferentiated and differentiated cells.
(D–F) The subcellular localization of the phospho-
proteins is shown; those widely associated with
more than one subcellular location are designated
as variable.
(G–I) Phosphoprotein categories, among those
whose functions are known, are shown. The
percentage of proteins with known functions are
45.8%, 55.7%, and 57.2% for proteins with more
phosphorylation site identifications in undifferenti-
ated hESCs, differentiated hESC derivatives, or
a similar number of phosphorylation site identifica-
tions between the two cell populations, respec-
tively. Each chart progresses from the protein
category containing themost to the fewest entries.
Abbreviationsanddefinitions include the following:
transcript. reg., transcription regulator; enzyme, protein with enzymatic activity outside of the other categories; RNA meta., RNA-binding proteins and proteins
participating in metabolic processes involving RNA; prot. degr., protein degradation; transport., transporter; apop. reg., apoptosis regulator; transmem. recep.,
transmembrane receptor; GEF and GAP, guanine nucleotide exchange factor and GTPase-activating protein; cytoskel., proteins that are components of, closely
associated with, or regulate cytoskeletal function; cell prolif., proteins participating in regulation of cellular proliferation and/or cell-cycle progression; tum. sup.,
tumor suppressor; translat. reg., translation regulator; phosphoinos. sig., proteins participating in phosphoinositide signaling; gen. assem., genomeassembly; GF,
growth factor; cell adhes., proteins functioning in cell adhesion; telomeremainten., protein functioning in telomeremaintenance; prom. differ., proteins promoting
cellular differentiation; GF buffer, proteins regulating the availability of growth factors; comp. casc., complement cascade; nuc. receptor, ligand-dependent
nuclear receptor; and hormone biosyn., hormone biosynthesis.158 phosphorylated transcription regulators, 41 contained more
phosphorylation site identifications in undifferentiated hESCs,
46 contained more phosphorylation site identifications in differ-
entiated hESC-derivatives, and 71 contained a similar number
of phosphorylation site identifications in both cell populations.
Most of the transmembrane receptors and predicted extracel-
lular proteins contained more phosphorylation site identifica-
tions in either undifferentiated or differentiated hESCs, whereas
fewer of these proteins contained a similar number of phosphor-
ylation site identifications in both cell populations (Figures 2D–2I,
Table S6), implying that growth factors, cytokines, their recep-
tors, and corresponding signaling pathways could participate
in controlling hESC fate. Furthermore, kinases, which are key
players in cell signaling, represented the second-largest cate-gory of known phosphoproteins (Figures 2G–2I). Phosphoryla-
tion of cytoplasmic, cytoskeletal, and cell-adhesion proteins
was identified relatively frequently in differentiated derivatives
(Figures 2D–2I).
Phosphorylated Transcription Regulators
in Undifferentiated hESCs
The transcription regulator ESG1 (official symbol TLE1; Table S7)
is expressed only in preimplantation embryos, ESCs, and
primordial germ cells (Western et al., 2005). ESG1 is coex-
pressed with OCT4 and SOX2 in both mouse and human
ESCs, suggesting it is a potential pluripotency marker (Western
et al., 2005). In addition, SUPT16H and SSRP1 (Tables S7 and
S8) were phosphorylated in undifferentiated hESCs and are theCell Stem Cell 5, 204–213, August 7, 2009 ª2009 Elsevier Inc. 207
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Human ESC PhosphoproteomicsTable 1. Signaling Proteins with More Phosphorylation Site Identifications in Undifferentiated hESCs than in hESC Derivatives
Proteins Participating in Receptor Tyrosine Kinase Signaling
Receptors, Growth
Factors Kinases Phospholipases Adaptors Other
AREGa, KDR,
IGF2R, EPHA1
LCK, NEK4, MAPK6,
MAPK7, FRAP1 (mTOR),
PIK3C3, PIK3R4, DBF4,
CDC42BPA, CRKL, MINK1,
KIAA1804 (MLK4), CDKL5,
EIF2AK1, CRKRS
PLCG1, PLCG2, PLCH1 SHC1, GAB1, NCK2,
KIAA1303 (RAPTOR),
CNKSR1, CNKSR2, ABI2,
CDC37L1, PLEKHA1
PPAP2B, EPS15L1, TRAF4,
APC, CDH17, IGFBP2,
RAPGEF1,
TRIP10, TSC1, WDR62,
NUMB
Signal Transduction Pathways and Member Proteins
MAPK: JNK, ERK CRKLb, MINK1, KIAA1804 (MLK4), TRAF4, TRIP10, WDR62, CNKSR1, DBF4, CDC42BPA, RAPGEF1, PLCG1,
SHC1, PLCG2, GAB1, LCK, MAPK6, MAPK7, NEK4, NCK2
PI3K/AKT/mTOR FRAP1 (mTOR), TSC1, GAB1, PIK3C3, PLCG2, PIK3R4, KIAA1303 (RAPTOR), ANRT (HIF-1b)
a Official symbols of the proteins, some of which are followed by synonyms in parentheses, are used in this table.
b Symbols in bold text represent proteins that are relatively specific to JNK signaling.two subunits of FACT (facilitates chromatin transcription). FACT
destabilizes nucleosomes to allow transcription without disrup-
tion of the epigenetic state (Belotserkovskaya et al., 2003) and
promotes initiation of DNA replication in the S phase of the cell
cycle (Tan et al., 2006). CREBBP (Table S7) has histone acetyl-
transferase activity. Its mRNA is enriched in undifferentiated
hESCs (Brandenberger et al., 2004) (Table S8). AKT (Table
S5A) phosphorylates CREBBP, increasing CREBBP acetyltrans-
ferase activity and promoting NF-kB-mediated transcription and
enhanced cell survival (Liu et al., 2006). Furthermore, CREBBP
increases ERK1 expression (Chu et al., 2005). ERK1 activity
contributes to hESC self-renewal in the presence of bFGF (Li
et al., 2007).
At least 18 phosphorylated transcription regulators identified
in undifferentiated hESCs can modify chromatin structure via
histone methylation or acetylation (Table S7) and may contribute
to the epigenetic pattern that is likely to be important to hESCs
(Bernstein et al., 2006; Lee et al., 2006; McCool et al., 2007).
We identified phosphorylation of DNMT3B, MBD3 (Table S3A)
and EZH2 (Table S5A) in undifferentiated hESCs. DNMT3B
encodes a DNA methyltransferase (Table S7), which was ex-
pressed in all 59 hESC lines tested (Adewumi et al., 2007), was
enriched in undifferentiated hESCs (Brandenberger et al.,
2004), and was phosphorylated in undifferentiated hESCs (Table
S8). Differential phosphorylation could modulate EZH2 activity.
Phosphorylation at S21 by AKT inhibits the histone H3 Lys27
methyltransferase activity of EZH2 (Cha et al., 2005), and we
identified a phosphorylation site of EZH2 in undifferentiated
hESCs (S371 or T372; Table S5A), a site whose phosphorylation
was also identified in undifferentiated mouse ESCs (L.M.B.,
K.-B.L., W.X., and S.D., unpublished data).
Phosphorylated transcription regulators in undifferentiated
hESCs can participate in transcriptional activation or repression,
histonemodification, andmore (Table S7). These and other func-
tions may be integrated to favor the undifferentiated state of
hESCs, as implied by the complexity of the phosphoproteome
(Figure 2). Although some of these transcriptional and epigenetic
regulators were previously reported to influence hESCs, the
mechanisms are unclear. The identified phosphorylation sites
provide focused information for future studies of the function
of these factors in hESCs. Furthermore, we also identified208 Cell Stem Cell 5, 204–213, August 7, 2009 ª2009 Elsevier Inc.hundreds of phosphoproteins whose presence in hESCs was
unknown, providing a rich resource for further investigation.
For instance, TNRC6A, a factor for gene silencing via RNA inter-
ference (Liu et al., 2005), was phosphorylated in undifferentiated
hESCs (Table S3A).
Growth Factor-Mediated Signaling Pathways
in Undifferentiated hESCs
Tyrosine phosphorylation, which plays a dominant role in growth
factor/RTK signaling pathways (Schlessinger, 2000), was rela-
tively prominent in undifferentiated hESCs (Figure 2C). Signaling
pathways participating in self-renewal of hESCs include bFGF,
TGF-b/activin, insulin/IGF, EGFR family, PDGF, Wnt, neurotro-
phin, integrin, and Notch pathways (Beattie et al., 2005; Bendall
et al., 2007; James et al., 2005; Pebay et al., 2005; Wang et al.,
2007; Xu et al., 2005; Yao et al., 2006). However, detailed under-
standing of the action of these pathways is lacking. The phos-
phoproteinswere grouped into signaling pathways, as described
in the Supplemental Experimental Procedures, to further explore
their functional potential. Forty-one canonical and metabolic
pathways were suggested using the phosphoproteins as input
for pathway analysis (data not shown). Proteins in RTK pathways
were phosphorylated in undifferentiated hESCs, including the
adaptors GAB1, SHC1, and NCK2; the kinases LCK, NEK4,
MAPK6, MAPK7, mTOR, PIK3C3, and PIK3R4; phospholipases
PLC-g1 and PLC-g2; and the phosphatase PPAP2B (Table 1).
Some phosphoproteins are shared among pathways, and
some are more pathway specific, such as APC in Wnt signaling
and NUMB in Notch signaling. Table 1 and Figure 2C imply that
a variety of signaling pathways are important in undifferentiated
hESCs. For example, EGF pathway members ErbB2, AREG,
and EPS15L1 were phosphorylated in undifferentiated hESCs
(Table 1 and Table S5), complementing a report showing that
the ErbB2/ErbB3 ligand heregulin-1b helps support undifferenti-
ated hESCs (Wang et al., 2007). KDR (VEGFR2, FLK1) was
phosphorylated in undifferentiated hESCs (Table 1), and stimula-
tion of hESCs with CM elicits tyrosine phosphorylation (site[s]
undefined) of PDGFRA (Wang et al., 2007). Components of
the VEGF and PDGF pathways were phosphorylated in undiffer-
entiated hESCs, including some proteins in Table 1. We also
identified phosphoproteins from signaling pathways whose
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proteins not previously known to be phosphorylated (Tables
S3A–S5B).
Molecular profiling studies typically lack biological follow-up
(e.g., Bodenmiller et al., 2007; Boyer et al., 2005; Brandenberger
et al., 2004; Brill et al., 2004; Ficarro et al., 2005; Gruhler et al.,
2005; Lee et al., 2006; McCool et al., 2007; Sperger et al.,
2003; Thingholm et al., 2008a, 2008b; Van Hoof et al., 2006).
However, a few, including transcriptomic (Armstrong et al.,
2006) and proteomic (Bendall et al., 2007; Kratchmarova
et al., 2005; Mukherji et al., 2006; Wang et al., 2006; Wang
et al., 2007) studies, demonstrated that cells responded to stim-
ulation in manners consistent with molecular profiles. To test the
cellular relevance of the phosphoproteomic and pathway anal-
yses, we began by targeting EGF, VEGF, and PDGF pathways
in undifferentiated hESCs using inhibitors of their receptors.
Although specificity of RTK inhibitors is imperfect, we used
some of the widely accepted ones (see the Supplemental Exper-
imental Procedures). Treatment of undifferentiated hESC
cultures with an EGFR inhibitor at 10 mM resulted in extensive
apoptosis (data not shown), similar to another report (Wang
et al., 2007). The hESCs were also treated with 10 mMKDR inhib-
itor II or 10 mMGleevec, a PDGFRA inhibitor (Zhang et al., 2003).
Undifferentiated control colonies were compact and expressed
OCT4 and SSEA-4 (Figure 3B and data not shown). In contrast,
most cells differentiated in the presence of KDR or PDGFR
inhibitor, shown by flattening of the colonies, altered cellular
morphology and nearly undetectable OCT4 and SSEA-4
(Figure 3C and data not shown). Vehicle-only controls lacked
any noticeable effect on the cells (Figure 3B). The results were
similar under feeder-free conditions in CM and feeder-free
conditions in chemically defined media (CDM; Yao et al.,
2006). Furthermore, KDR or PDGFR inhibitor, at 10 mM, resulted
in decreased expression of NANOG and OCT4 (Figure 3A).
To further investigate the effect of RTK signaling pathways, we
decreased bFGF to a subthreshold 4 ng/ml (at least 20 ng/ml is
required under feeder-free conditions in CDM [Yao et al.,
2006]) and systematically supplemented cultures with EGF,
PDGF-AA, or VEGF-AA at different concentrations to determine
which trophic factor could complement bFGF deficiency.
Although PDGF-AA without bFGF was unable to maintain long-
term cultures of undifferentiated hESCs, PDGF-AA at 10 ng/ml
and the subthreshold concentration of 4 ng/ml of bFGF (subse-
quently abbreviated PDGF/bFGF) stably maintained undifferen-
tiated hESCs under feeder-free conditions in CDM for >15
passages, and the hESCs remained undifferentiated throughout
all four experiments (Figure 4D). The cells displayed undifferenti-
ated morphology and robust expression of OCT4. In contrast,
when undifferentiated hESCs, which had been stably maintained
in CDM containing PDGF/bFGF for >15 passages, were subse-
quently cultured for 4 days in CDM containing 4 ng/ml of bFGF
but no PDGF, the cells differentiated (Figure 4B). FACS analyses
demonstrated that 89% of the hESCs in CDM containing
PDGF/bFGF were positive for SSEA-4, comparable to cultures
in CDM containing 20 ng/ml of bFGF (86%; Figure 4). Similar
FACS results were obtained when cells were stained and sorted
for the pluripotency marker Tra-1-60 (data not shown). More-
over, PDGF/bFGF in CDM resulted in sustained expression of
NANOG and OCT4 transcripts, whereas their abundancedeclined within 4 days in the absence of PDGF-AA or the pres-
ence of the PDGFR inhibitor Gleevec (Figures 3A and 4A), further
supporting the proposal that PDGF-AA facilitates maintenance
of undifferentiated hESCs. Together, phosphoproteomic and
pathway analyses suggested that PDGF should favor mainte-
nance of undifferentiated hESCs. PDGFR inhibitor, and separate
use of PDGF-AA, provided clear evidence that PDGF, when
bFGF is at a subthreshold concentration, can promote the
undifferentiated state of hESCs in CDM under feeder-free condi-
tions, insights that derived directly from the phosphoproteomic
analysis.
Our data further suggested that ErbB and VEGFR activation
participate in maintenance of undifferentiated hESCs, because
disruption of these pathways caused apoptosis (data not shown)
and/or differentiation (Figure 3) (although EGF and VEGF-AA
demonstrated limited efficacy at complementing the deficiencies
of 4 ng/ml bFGF). The ErbB2/ErbB3 ligand heregulin-1b contrib-
utes to maintenance of undifferentiated hESCs (Wang et al.,
2007). In addition, insulin/IGF pathway members (Bendall et al.,
2007) were phosphorylated in hESCs (including proteins in the
PI3K/AKT/mTOR pathway; Table 1).
Phosphoproteomics, cellular assays, and other reports (Bend-
all et al., 2007; Wang et al., 2007; Yao et al., 2006) suggest that
multiple RTK pathways are required, although none of them
alone is sufficient to support self-renewal in the absence of
Figure 3. Protein Kinase Inhibitors Resulted in Differentiation of
hESCs
(A) Expression of NANOG (Chambers et al., 2003) and OCT4 mRNAs was as-
sessed by RT-PCR, in the presence of protein kinase inhibitors that resulted in
differentiation of hESCs. Cells were cultured with 20 ng/ml of bFGF, and inhib-
itors (10 mM) were included in the cultures for the final 4 days. Inhibitor identi-
ties are indicated in the figure. Slower decline of OCT4 than NANOGwas typi-
cally observed during hESC differentiation. GAPDH was an internal control.
(B and C) Undifferentiated, vehicle-only control (B) and differentiated, KDR
inhibitor-treated (C) cells are shown under imaging conditions indicated above
the columns. All photomicrographs were at the same magnification, and the
scale bar (bottom right) represents 50 mM. Abbreviations include the following:
i, inhibitor; uhESCs, undifferentiated hESCs.Cell Stem Cell 5, 204–213, August 7, 2009 ª2009 Elsevier Inc. 209
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the undefined media that was used, Sphingosine-1-phosphate
plus PDGF contributes to maintenance of undifferentiated
hESCs in the presence of mouse embryonic fibroblasts (MEFs)
or MEF-conditioned media (Pebay et al., 2005). It previously
appeared that bFGF alone might sustain self-renewal of hESCs.
However, as predicted by our phosphoproteomic analysis,
several other factors that exist in serum and/or are secreted by
feeders, acting through autocrine or paracrine effects or as
culture additives, are also important for hESC self-renewal
(Bendall et al., 2007; Wang et al., 2007). Our phosphoproteomic
Figure 4. PDGF and a Subthreshold Concentration of bFGF Sus-
tained Long-Term Culture of hESCs
(A) RT-PCR to amplify NANOG and OCT4 transcripts in long-term hESC
cultures (>15 passages) in CDM containing 10 ng/ml of PDGF-AA and 4 ng/
ml of bFGF (lane PDGF, bFGF4). Lanes bFGF20 or bFGF4 refer to 20 or
4 ng/ml of bFGF in the CDM for 4 days, respectively, in the absence of
PDGF, following culture in 10 ng/ml of PDGF-AA and 4 ng/ml of bFGF for
>15 passages.
(B–D) Colony morphology, OCT4 staining, and fluorescence-activated cell
sorting (FACS) demonstrated that PDGF/bFGF in CDMmaintained undifferen-
tiated hESCs passaged >15 times. Imaging conditions or FACS analyses of
SSEA-4 expression, detected via Cy3-conjugated secondary antibodies, is
indicated above the columns, and the culture additives that were varied are
indicated beside the rows. In FACS plots, dotted lines delineate boundaries
of fluorescence intensity approximately indicative of cellular identity as undif-
ferentiated hESCs (uhESC) and differentiated hESC derivatives (deriv). Decline
of SSEA-4 is incomplete in differentiated hESCs after 4 days (Figure 1).
Following maintenance of the hESCs in CDM containing bFGF at 4 ng/ml
and PDGF-AA at 10 ng/ml for >15 passages, cells were cultured for 4 days
in CDM lacking PDGF and containing bFGF at 4 ng/ml (B) or 20 ng/ml (C), or
in the continued presence of bFGF at 4 ng/ml and PDGF-AA at 10 ng/ml (D).
All photomicrographs were at the same magnification, and the scale bar
(bottom center panel) represents 100 mM (B–D).210 Cell Stem Cell 5, 204–213, August 7, 2009 ª2009 Elsevier Inc.and pathway analyses also imply that additional pathways could
favor undifferentiated hESCs.
Phosphorylated Signal Transduction Proteins
in Undifferentiated hESCs
PI3K signaling facilitates ESC self-renewal (Armstrong et al.,
2006), and the PI3K pathway is activated by PDGF in mesen-
chymal stem cells (Kratchmarova et al., 2005), but the mecha-
nism of action of the PI3K pathway has been unclear. PI3K/
AKT/mTOR pathway members were phosphorylated in undiffer-
entiated hESCs. For example, PIK3C3 is enriched in undifferenti-
ated hESCs (Brandenberger et al., 2004), and PIK3C3 was phos-
phorylated in undifferentiated hESCs (Table 1). mTOR (Table 1)
plays a role in proliferation of undifferentiated hESCs (Wang
et al., 2007) and is phosphorylated at Ser2448 during mitogenic
stimulation (Chiang andAbraham, 2005).mTOR, phosphorylated
at Ser2448 and Ser2454 in undifferentiated hESCs (Figure S3A,
Table S3A) is a protein that enhances cell survival (Peponi et al.,
2006). TSC1 was also phosphorylated in undifferentiated hESCs
(Table 1). TSC1 can limit cell size (Rosner et al., 2003), and its
overexpression caused cells to form compact clusters with
increased reaggregation in vitro (Li et al., 2003), similar to the
small size of undifferentiated hESCs and compact morphology
of hESC colonies. Phosphorylated PI3K/AKT/mTOR pathway
members in undifferentiated hESCs (Table 1) suggest which
pathway members may regulate undifferentiated hESCs.
Phosphoproteins participating in MAPK signaling were identi-
fied (Table 1). The ERK pathway contributes to hESC self-
renewal under conditions that include bFGF (Li et al., 2007),
whereas JNK signaling in hESCs has not been reported. Some
phosphoproteins downstream of RTK pathways are relatively
specific to JNK signaling, such as TRAF4, MLK4, CRKL, and
MINK1 (Table 1). To test for JNK signaling in undifferentiated
hESCs, we tested two JNK inhibitors in hESC cultures under
feeder-free conditions in CM. JNK inhibitor II, a small molecule
(SP600125) widely used in JNK studies (Bennett et al., 2001;
Han et al., 2001; Shin et al., 2002), and JNK inhibitor III, a poly-
peptide (Holzberg et al., 2003), were used. Each inhibitor alone
resulted in cellular differentiation, demonstrated by colony
morphology and decreased OCT4 expression (Figure S4). In
contrast, controls lacking JNK inhibitors, including vehicle-only
controls, remained undifferentiated (Figure S4 and data not
shown). Induction of differentiation by JNK inhibitors was similar
under feeder-free conditions in CDM (data not shown). Further-
more, OCT4 and NANOG mRNA was depleted in the presence
of JNK inhibitor II (Figure 3A). Thus, this phosphoproteomic anal-
ysis provides the first suggestion that JNK, an important signal
transduction protein downstream of many RTKs, may facilitate
maintenance of undifferentiated hESCs. Moreover, these exper-
iments further demonstrate agreement between phosphopro-
teomic and cellular analyses in hESCs.
DISCUSSION
Analysis of molecular mechanisms underlying hESC properties
is essential for optimal use of these cells. Complementing
previous analyses of promoters, transcripts, and protein expres-
sion, our phosphoproteomic analysis suggests that multiple
protein phosphorylation events participate in control of hESC
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Human ESC Phosphoproteomicsfate. Application of MDLC-MS/MS-based phosphoproteomics
to pluripotent cells may represent an important tool for stem
cell biologists. While this study focused on its use for hESCs,
one can envision its application to induced pluripotent somatic
cells and other somatic stem cells.
Our phosphoproteomic analyses identified proteins potentially
participating in self-renewal or differentiation of hESCs and
focused attention on pathways heretofore underappreciated
and underexplored. Transcription regulators, including epige-
netic and transcription factors, and kinases contained many
phosphorylated members, suggesting that these proteins may
be key determinants of hESC fate decisions. Although a variety
of proteins have been implicated in hESC self-renewal, some
of their functions have been unclear. The identified phosphoryla-
tion sites, some on central signaling proteins, expand the knowl-
edge of protein phosphorylation in hESCs. We also identified
many proteins whose potential functions in hESCs had not
been identified previously. In other words, phosphoproteomic
analysesmay provide guidance for systematic, rather than solely
serendipitous or overly broad-based, approaches in future
studies of self-renewal and differentiation of pluripotent cells.
Phosphoproteomic analyses identified proteins favoring an
undifferentiated or differentiated state of hESCs. For example,
phosphorylation of proteins in the JNK pathway was identified,
and our cellular follow-up experiments, which are atypical of
molecular profiling studies, suggested that inhibition of JNK
leads to differentiation of hESCs. A role of JNK in undifferenti-
ated hESCs has not been reported. The VEGF and PDGF path-
ways are candidates to favor maintenance of undifferentiated
hESCs because inhibitors of their receptors resulted in hESC
differentiation. However, the growth factors that were added
singly could not replace bFGF. Together, these results sug-
gested that activation of these pathways is necessary but not
sufficient to sustain self-renewal of hESCs, consistent with
increasing evidence that multiple growth factor-driven pathways
act together to maintain undifferentiated hESCs. For example,
PDGF-AA complemented a subthreshold concentration of
bFGF, shown by long-term maintenance of undifferentiated
cultures under feeder-free conditions in CDM. Use of CDM al-
lowed improved knowledge of the composition of the media,
rather than use of undefined media in the presence of, or condi-
tioned by, feeder fibroblasts (Yao et al., 2006), so the pathways
that were targeted in our cellular assays were more clearly
defined. Together, our results expanded the repertoire of path-
ways that facilitate hESC culture and support the suggestion
that multiple signaling inputs are needed to maintain undifferen-
tiated hESCs (Wang et al., 2007). Moreover, phosphoproteomic
analyses complement epigenetics, gene expression profiles,
and total protein MS to facilitate an improved understanding of
hESC fate determination.
The functions of most of the phosphorylated proteins in plurip-
otent cells are unknown and should be evaluated for their influ-
ence on stem cell behavior. Application of further advances in
proteomic and allied technologies should enhance future studies
through improved analysis of protein phosphorylation. As phos-
phoproteins controlling pluripotent behavior are understood
better, methods for developing model systems with stem cells,
and potential therapeutic applications may become increasingly
clear.EXPERIMENTAL PROCEDURES
Cell Culture, Phosphoproteomic Analysis
Feeder-free cultures were in Matrigel-coated plates in CM containing 8 ng/ml
bFGF (Xu et al., 2001). Differentiation was with 5 mMRA and no added bFGF. In
CDM, hESCs were cultured in Matrigel-coated plates in N2/B27-CDM (Yao
et al., 2006). Phosphoproteomic analyses used cells from CM. Cells were
rinsed with PBS, lysed, and centrifuged, and proteins were precipitated with
(NH4)2SO4 and pelleted by centrifugation.
Proteins were resuspended in 100mMNH4HCO3, 8Murea containing phos-
phatase inhibitors, reduced, alkylated, digested with trypsin, and peptides
desalted. Peptides were separated by SCX, phosphopeptides enriched by
desalt-IMAC (Brill et al., 2004; Ficarro et al., 2005), separated by nanoflow
HPLC, and analyzed by ESI-MS/MS. MS/MS spectra were matched to amino
acid sequences using SEQUEST (Eng et al., 1994). All reported phosphopep-
tide identifications were manually verified (Bernstein et al., 2008; Brill et al.,
2004; Ficarro et al., 2005).
Normalized XIC peak areas of some phosphopeptides were quantified. For
analyses lacking the identification, MS/MS data were exhaustively searched
for the phosphopeptide, which was rarely found via a poor quality MS/MS
spectrum, and its XIC peak area was quantified.
Phosphoproteins were classified as containing more phosphorylation site
identifications in undifferentiated hESCs or differentiated derivatives, or as
containing a similar number of phosphorylation site identifications in the two
cell populations, as described in the Results.
Western Blot Analysis
Proteins were run on Bis-Tris gels, transferred to PVDF membranes, blocked,
and incubated with antibodies recognizing phosphorylation sites identified
by MDLC-MS/MS. Anti-GAPDH was the loading control. Membranes were
washed, incubated with fluorophore-conjugated secondary antibodies,
washed, imaged, andbandsquantifiedaccording to themanufacturer (LI-COR).
Phosphoprotein Category, Subcellular Location, and Pathway
Analysis
Ingenuity Pathway Analysis, Metacore, NCBI, Gene Ontology, and peer-
reviewed literature were used to identify phosphoprotein subcellular location,
category, and signaling pathways.
Cellular Assays, RT-PCR
EGFR, JNK, or PDGFR inhibitors were used. Untreated and vehicle-only
controls were included for each experiment. PDGF-AA/bFGF was used in
cultures for >15 passages.
For immunostaining and DAPI staining, monoclonal mouse anti-OCT4 and
anti-SSEA-4 were used. Secondary antibodies were Cy2-conjugated rabbit
anti-mouse IgM and Cy3-conjugated rabbit anti-mouse IgG. For RT-PCR,
mRNA was isolated and cDNA was synthesized; OCT4, NANOG, and GAPDH
were amplified. For FACS, cells were incubated with mouse monoclonal anti-
SSEA-4 or anti-TRA-1-60 antibodies, washed with PBS, and incubated with
Cy3-conjugated rabbit anti-mouse IgG.
Details are in the Supplemental Experimental Procedures.
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